UBS Group’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-229,072
| Closed | -$1.03M | – | 11031 |
|
|
2025
Q2 | $1.03M | Buy |
229,072
+137,496
| +150% | +$618K | ﹤0.01% | 5430 |
|
|
2025
Q1 | $406K | Buy |
91,576
+52,644
| +135% | +$306K | ﹤0.01% | 6018 |
|
|
2024
Q4 | $305K | Sell |
38,932
-5,654
| -13% | -$68.9K | ﹤0.01% | 6191 |
|
|
2024
Q3 | $586K | Buy |
44,586
+25,582
| +135% | +$324K | ﹤0.01% | 5098 |
|
|
2024
Q2 | $230K | Sell |
19,004
-18,543
| -49% | -$250K | ﹤0.01% | 5573 |
|
|
2024
Q1 | $611K | Buy |
37,547
+803
| +2% | +$10.8K | ﹤0.01% | 5033 |
|
|
2023
Q4 | $251K | Buy |
36,744
+17,211
| +88% | +$99.5K | ﹤0.01% | 5628 |
|
|
2023
Q3 | $106K | Sell |
19,533
-1,534
| -7% | -$8.93K | ﹤0.01% | 5795 |
|
|
2023
Q2 | $143K | Sell |
21,067
-55,196
| -72% | -$414K | ﹤0.01% | 5723 |
|
|
2023
Q1 | $382K | Buy |
+76,263
| New | +$311K | ﹤0.01% | 4900 |
|
|
2022
Q4 | – | Sell |
-12,594
| Closed | -$182K | – | 11216 |
|
|
2022
Q3 | $182K | Sell |
12,594
-12,975
| -51% | -$215K | ﹤0.01% | 5178 |
|
|
2022
Q2 | $387K | Sell |
25,569
-108,608
| -81% | -$1.27M | ﹤0.01% | 4452 |
|
|
2022
Q1 | $1.59M | Buy |
134,177
+69,728
| +108% | +$716K | ﹤0.01% | 3654 |
|
|
2021
Q4 | $1.04M | Buy |
64,449
+38,890
| +152% | +$831K | ﹤0.01% | 4352 |
|
|
2021
Q3 | $729K | Buy |
25,559
+24,207
| +1,790% | +$763K | ﹤0.01% | 4452 |
|
|
2021
Q2 | $45K | Buy |
1,352
+1,247
| +1,188% | +$40K | ﹤0.01% | 6537 |
|
|
2021
Q1 | $3K | Buy |
105
+50
| +91% | +$2.05K | ﹤0.01% | 8539 |
|
|
2020
Q4 | $3K | Buy |
55
+39
| +244% | +$1.8K | ﹤0.01% | 8022 |
|
|
2020
Q3 | $1K | Sell |
16
-203
| -93% | -$8.08K | ﹤0.01% | 7849 |
|
|
2020
Q2 | $9K | Sell |
219
-4,922
| -96% | -$186K | ﹤0.01% | 7099 |
|
|
2020
Q1 | $134K | Buy |
5,141
+4,941
| +2,471% | +$143K | ﹤0.01% | 5036 |
|
|
2019
Q4 | $6K | Sell |
200
-15,583
| -99% | -$461K | ﹤0.01% | 7539 |
|
|
2019
Q3 | $411K | Buy |
15,783
+13,423
| +569% | +$343K | ﹤0.01% | 4724 |
|
|
2019
Q2 | $54K | Buy |
2,360
+887
| +60% | +$20.4K | ﹤0.01% | 5860 |
|
|
2019
Q1 | $39K | Sell |
1,473
-2,201
| -60% | -$48.3K | ﹤0.01% | 5739 |
|
|
2018
Q4 | $75K | Buy |
+3,674
| New | +$84.4K | ﹤0.01% | 5787 |
|
Other funds holding YMAB
UBS Group's YMAB Position: Q3 2025 in Review
UBS Group sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 229,072 shares — an estimated $1.03M sold.
UBS Group first reported a position in YMAB in Q4 2018 and held it in 26 quarters. The position peaked at $1.59M in Q1 2022. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- UBS Group reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- UBS Group sold 229,072 Y-mAbs Therapeutics shares in Q3 2025, an estimated $1.03M.
- UBS Group first reported a position in Y-mAbs Therapeutics in Q4 2018 and held it in 26 quarters.
- UBS Group's Y-mAbs Therapeutics position peaked at $1.59M in Q1 2022.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.